Developing smarter assessment solutions

Addressing Important Health Issues

Quadrant Biosciences is dedicated to seeking solutions to important global health issues such as concussion, Autism Spectrum Disorder and Parkinson’s Disease.

Situation: Concussion And Brain Health

This year in the US alone, 1.6 to 3.8 million athletes will experience a sports-related concussion. Despite increased public awareness, the standard tools used to evaluate and treat a concussion — self-reported symptoms and expert opinion — offer poor reliability and sensitivity. Consequently, many of these injuries are misdiagnosed, creating a heightened risk of serious secondary injuries if the athlete prematurely returns to play.

Understandably, physicians are frustrated with the absence of credible tools to objectively and quantitatively assess head injuries and the critical return-to-play decision; parents are worried about the health of their children and the unseen consequences of their injuries; and athletes are concerned about the extent of their injuries and unclear about the timeline for recovery.

Quadrant Biosciences is currently working on solutions to this problem on two fronts: functional assessment and epigenetic biomarkers.

Solution: The ClearEdge Brain Health Toolkit

JUST LAUNCHED AND AVAILABLE IN THE U.S.!

The ClearEdge Brain Health Toolkit represents a new standard of care that offers clinical best practices with cloud-based analytics. The ClearEdge Toolkit provides clinicians a suite of testing applications that are:

Complete - ClearEdge provides clinicians a suite of tests and assessments to establish baselines and track brain health and wellness over time. The toolkit is comprised of separate tests for cognitive efficiency, balance assessment and symptoms tracking.

Objective - Patient test results are quantitatively analyzed relative to prior performance

Clinically reliable - The preliminary test-retest reliability assessment indicates that the system will be appropriate for clinical decision-making

Evolutionary - Academic research is translated to clinical practice

Cost Effective - The system’s low cost of acquisition and short testing interval facilitate time and revenue efficiencies using existing CPT codes

Portable - The entire system fits in a briefcase; ClearEdge testing can occur almost anywhere

Solution: Concussion Biomarker In Saliva

Despite a strong focus by researchers over the past several years, identifying  a reliable biomarker test to objectively diagnose concussion has remained elusive. However, research we are conducting in cooperation with Penn State College of Medicine and SUNY Upstate Medical University, may change that. Focusing on epigenetic microRNA in the saliva, we have identified a novel and accurate biomarker for concussion in children. Among the significant findings of this research include:

Saliva is a Rich Source – microRNA’s have been found in relative abundance in the saliva which, when coupled with their unique epigenetic properties, make them attractive biomarker candidates

Accurate Differentiation – Six microRNAs had parallel changes in CSF and saliva and could accurately separate concussion and control cases

Predictive of Symptom Duration – The study also showed compelling data that this biomarker may be a better predictor of symptom (headache, fatigue, difficulty concentrating, etc) duration than current standard concussion assessments.

Results of this research were published in the highly regarded, peer-reviewed journal JAMA Pediatrics in November 2017.

Situation: Autism

Autism Spectrum Disorder (ASD) is a medical condition that affects a person’s communication abilities and social skills, and often causes repetitive patterns of behavior and a narrow range of interests. The number of children diagnosed annually with ASD has increased significantly between 2000 and 2010, from one in 150 to one in 68.

Although there is no known cure for autism, early intervention with behavioral therapies (e.g., Applied Behavioral Techniques) has been shown to reduce the severity of symptoms and the disabling aspects of the condition. However, early intervention requires early diagnosis, and existing diagnostic tests lack the essential specificity to ASD to make them a useful tool for early screening.

Solution: Autism Screening Test

In cooperation with SUNY Upstate Medical Center and Penn State College of Medicine, Quadrant Biosciences has developed a unique test that facilitates the early diagnosis of ASD. Our autism screening test, which involves specific biomarkers, has been yielding impressive sensitivity and specificity numbers. This groundbreaking technology is expected to be commercially available in 2018.

Situation: Parkinson’s Disease

Parkinson’s disease is a chronic, degenerative neurological disorder of the central nervous system. It results from the progressive loss of cells in various parts of the brain that produce dopamine, a chemical messenger responsible for transmitting signals that allow for coordinated movement.

Parkinson’s affects one in 100 people over age 60 and more than five million people worldwide. Currently there is no objective test or biomarker for Parkinson’s Disease, and the rate of misdiagnosis can be relatively high, especially when the diagnosis is made by a non-specialist.

Solution: Parkinson’s Screening Test

In cooperation with SUNY Upstate Medical University, Quadrant Biosciences has developed a non-invasive, saliva biomarker test highly accurate in characterizing Parkinson’s Disease through an evaluation of human and oral microbiome transcripts.  Commercial launch of this technology is expected in early 2019.